Patent · US Active

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

US11517570B2 · kind B2 · utility

1Cited by

48References

22Claims

0Family size

Assignee

Kronos Bio, Inc. · US

Inventors

Peter A. Blomgren · Issaquah, US
Kevin S. Currie · North Branford, US
Jeffrey E. Kropf · Branford, US
Seung H. Lee · Sammamish, US
Jennifer R. Lo · Plainsboro, US
Scott A. Mitchell · East Haven, US
Aaron C. Schmitt · Hamden, US
Sundaramoorthi Swaminathan · Burlingame, US
Jin-Ming Xiong · Guilford, US
Jianjun Xu · Bellevue, US
Zhongdong Zhao · Guilford, US

Key dates

Filing date	Oct 28, 2020
Grant date	Dec 6, 2022
Priority date	—
Expiry date	Apr 11, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.